Skip to main content
SpringerLink
Log in

Alemtuzumab cost saving for CLL

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Scott WG, Scott HM.Economic evaluation of third line treatment with alemtuzumab for chronic lymphocytic leukaemia. Clinical Drug Investigation 27: 755-764, No. 11, 2007

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alemtuzumab cost saving for CLL. Pharmacoecon. Outcomes News 540, 12 (2007). https://doi.org/10.2165/00151234-200705400-00023

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705400-00023

Keywords

Search

Navigation